Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman Sells 60,984 Shares

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 60,984 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $1.50, for a total value of $91,476.00. Following the transaction, the chief executive officer now directly owns 4,309,758 shares in the company, valued at $6,464,637. This represents a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

William Mariner Greenman also recently made the following trade(s):

• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The stock was sold at an average price of $1.55, for a total value of $35,685.65.

Cerus Stock Performance

NASDAQ CERS traded down $0.04 on Monday, reaching $1.47. 1,812,528 shares of the company’s stock traded hands, compared to its average volume of 1,306,882. The firm has a market cap of $273.11 million, a price-to-earnings ratio of -13.36 and a beta of 1.56. The stock has a 50 day moving average price of $1.74 and a 200-day moving average price of $1.79. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.54. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. Equities research analysts predict that Cerus Co. will post -0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning boosted its holdings in Cerus by 51.3% during the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after buying an additional 8,411 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in Cerus by 153.7% during the third quarter. Los Angeles Capital Management LLC now owns 195,224 shares of the biotechnology company’s stock worth $340,000 after buying an additional 118,280 shares in the last quarter. Bouvel Investment Partners LLC boosted its holdings in Cerus by 87.1% during the third quarter. Bouvel Investment Partners LLC now owns 505,020 shares of the biotechnology company’s stock worth $879,000 after buying an additional 235,082 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Cerus during the third quarter worth $353,000. Finally, Intech Investment Management LLC purchased a new stake in Cerus during the third quarter worth $71,000. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research note on Friday, February 21st.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.